Related Experiment Video
Updated: Jun 4, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
Obesity in Hidradenitis Suppurativa: Are GLP-1 Receptor Agonists the New Frontier?
Jennifer Strong1, Marcia S Driscoll2
1Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD, USA. jastrong@som.umaryland.edu.
Abstract:
Hidradenitis suppurativa (HS) is an inflammatory skin disorder presenting with painful and draining nodules in intertriginous areas that may progress to sinus tracts. There is an increased prevalence of obesity in HS, and obesity may predispose patients to HS. Weight loss has been associated with improvement of HS symptoms. However, weight loss through diet modification, exercise or bariatric surgery has mixed results. Recently, glucagon-like peptide-1 (GLP-1) receptor agonists have been investigated for weight loss in HS. These drugs are effective for weight loss and reduce weight-related comorbidities, with few significant side effects. Early studies of liraglutide and semaglutide in HS have demonstrated improvement in disease severity and quality of life. GLP-1 receptor agonists are a promising therapy for patients with HS and may improve symptoms through decreased mechanical stress and moderation of inflammation.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Obesity
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Biguanides and Glitazones
GPCRs Regulate Adenylyl Cylase Activity
Hypodermis

